Apollomics announces results from Phase 3 bridging trial of uproleselan

Apollomics (APLM) announced the results from its Phase 3 bridging trial of uproleselan in China in patients with relapsed or refractory acute myeloid leukemia. The trial did not demonstrate favorable benefit for uproleselan. The median overall survival in the uproleselan arm was 9.3 months versus 14.3 months in the chemotherapy-only arm. Addition of uproleselan to chemotherapy was generally well tolerated, with a similar safety profile to the control arm. The incidence of serious adverse events was 43% in the uproleselan arm versus 39% in the chemotherapy-only arm. The most common serious adverse events in the uproleselan arm were decreased platelet count, infectious pneumonia, and sepsis.